12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sat, 24 May 2025 21:39:15 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Nel: {"success_fraction":0,"report_to":"cf-nel","max_age":604800} [5] => Report-To: {"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=uEHa6IEPEFGp1cm0VapvLRbSC90XjecqoKDWPaF3lZ9nfKUImaY%2BwRI%2B9VkoBXa%2B%2BOyiLxQ0XdINOagFlcR%2FfPOUHHJLZfSs8R6hgqj50etwcVL6EIKZYTcHyBJ6Y6Bg%2FTU%3D"}],"group":"cf-nel","max_age":604800} [6] => Server: cloudflare [7] => Vary: Accept-Encoding [8] => X-Powered-By: PHP/7.4.33 [9] => Cache-Control: no-cache, private [10] => Cf-Ray: 944ff1d43b709c13-KUL [11] => X-Frame-Options: SAMEORIGIN [12] => X-Xss-Protection: 1; mode=block [13] => X-Content-Type-Options: nosniff [14] => Referrer-Policy: no-referrer-when-downgrade [15] => Cf-Cache-Status: DYNAMIC [16] => Set-Cookie: UpalLiveSession=eyJpdiI6IlhKMU03WktoWGVVbzhyemlBRTlydXc9PSIsInZhbHVlIjoiVlpqZ2llXC84M3BKdnk2bkdUdEV4dnlRZ0dlQ2hzM0g0RjlUM05lTEhKeEF2elZLXC9HY1o0d2RUUmpnWXlGeDRzeW9rc2MrRzQrcTRSMDQyNW9ldm03QT09IiwibWFjIjoiNGE4ZTljNTI0NWJiNGM2ZTcwMGFlMjUzNmZjMzlhZGFiNTY2ZDNlZjFhMDIyZjI5OWZlNTlhOTY5NmQzYTkyNSJ9; HttpOnly; Path=/; Max-Age=94608000; Expires=Tue, 23 May 2028 20:43:37 GMT [17] => alt-svc: h3=":443"; ma=86400 [18] => server-timing: cfL4;desc="?proto=TCP&rtt=1065&min_rtt=984&rtt_var=364&sent=4&recv=7&lost=0&retrans=0&sent_bytes=3000&recv_bytes=756&delivery_rate=2907630&cwnd=252&unsent_bytes=0&cid=cfd1bc23ebd08b48&ts=21&x=0" ) 789

美国于6日将用在研究的抗病毒药物瑞德西韦（Remdesivir），成功治愈新冠肺炎患者。

首批收治患者的武汉市金银潭医院，于周四启动美国新药的临床试验，为308名轻至中症患者、453名重症患者进行“双盲试验”，评估它的疗效和安全性。

该试验计划预计完成时间为今年4月27日，试验组和对照组在第1天分别给予瑞德西韦和安慰剂200毫克负荷剂量，然后每天一次100毫克静脉内维持剂量，持续9天。

试验专案负责人曹彬指出，由于瑞德西韦治疗的病例仅有1宗，加上其第1期、第2期安全性试验是在境外完成，与中国存在人种差异，故必须执行严格的随机双盲试验，患者与医生都不清楚所服用的究竟是试验药还是安慰剂，直至揭盲时才能确信药物效果。

---

// // // //